157 related articles for article (PubMed ID: 29574002)
1. Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.
Ma VT; Boonstra PS; Menghrajani K; Perkins C; Gowin KL; Mesa RA; Gotlib JR; Talpaz M
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):e201-e210. PubMed ID: 29574002
[TBL] [Abstract][Full Text] [Related]
2. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
[TBL] [Abstract][Full Text] [Related]
3. [A study of prognostic value of cytogenetics in patients with primary myelofibrosis].
Li B; Xu J; Xu Z; Li C; Qin T; Fang L; Zhang H; Hu N; Pan L; Qu S; Wang J; Zhang Y; Zhang P; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):990-4. PubMed ID: 25417875
[TBL] [Abstract][Full Text] [Related]
4. Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis.
Menghrajani K; Boonstra PS; Mercer JA; Perkins C; Gowin KL; Weber AA; Mesa R; Gotlib JR; Wang L; Singer JW; Talpaz M
Leuk Lymphoma; 2019 Apr; 60(4):1036-1042. PubMed ID: 30234400
[TBL] [Abstract][Full Text] [Related]
5. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
6. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.
Tefferi A; Nicolosi M; Mudireddy M; Lasho TL; Gangat N; Begna KH; Hanson CA; Ketterling RP; Pardanani A
Leukemia; 2018 May; 32(5):1189-1199. PubMed ID: 29472717
[TBL] [Abstract][Full Text] [Related]
7. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
Tefferi A; Vaidya R; Caramazza D; Finke C; Lasho T; Pardanani A
J Clin Oncol; 2011 Apr; 29(10):1356-63. PubMed ID: 21300928
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis.
Li B; Zhang P; Feng G; Xu Z; Qin T; Zhang Y; Sha Z; Dong D; Zhang H; Fang L; Pan L; Hu N; Qu S; Cai W; Huang G; Xiao Z
Blood Cancer J; 2016 Dec; 6(12):e505. PubMed ID: 27935577
[No Abstract] [Full Text] [Related]
9. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia.
Strasser-Weippl K; Steurer M; Kees M; Augustin F; Tzankov A; Dirnhofer S; Fiegl M; Simonitsch-Klupp I; Gisslinger H; Zojer N; Ludwig H
Cancer; 2006 Dec; 107(12):2801-6. PubMed ID: 17103442
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis.
Tefferi A; Partain DK; Palmer JM; Slack JL; Roy V; Hogan WJ; Litzow ML; Ketterling RP; Patnaik MM
Am J Hematol; 2018 May; 93(5):649-654. PubMed ID: 29388258
[TBL] [Abstract][Full Text] [Related]
11. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
Mascarenhas J; Harrison CN; Kiladjian JJ; Komrokji RS; Koschmieder S; Vannucchi AM; Berry T; Redding D; Sherman L; Dougherty S; Peng L; Sun L; Huang F; Wan Y; Feller FM; Rizo A; Verstovsek S
Future Oncol; 2022 Jul; 18(22):2393-2402. PubMed ID: 35510486
[TBL] [Abstract][Full Text] [Related]
12. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.
Hussein K; Pardanani AD; Van Dyke DL; Hanson CA; Tefferi A
Blood; 2010 Jan; 115(3):496-9. PubMed ID: 19901264
[TBL] [Abstract][Full Text] [Related]
13. The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
Bose P; Verstovsek S
Cancer; 2016 Mar; 122(5):681-92. PubMed ID: 26717494
[TBL] [Abstract][Full Text] [Related]
14. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
Hidaka T; Shide K; Shimoda H; Kameda T; Toyama K; Katayose K; Kubuki Y; Nagata K; Takenaka K; Akashi K; Okamura T; Niho Y; Mizoguchi H; Omine M; Ozawa K; Harada M; Shimoda K
Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
[TBL] [Abstract][Full Text] [Related]
15. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A
Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439
[TBL] [Abstract][Full Text] [Related]
16. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features.
Coltro G; Rotunno G; Mannelli L; Mannarelli C; Fiaccabrino S; Romagnoli S; Bartalucci N; Ravenda E; Gelli E; Sant'Antonio E; Patnaik MM; Tefferi A; Vannucchi AM; Guglielmelli P
Blood Adv; 2020 Aug; 4(15):3677-3687. PubMed ID: 32777067
[TBL] [Abstract][Full Text] [Related]
17. The role of therapy in the outcome of patients with myelofibrosis.
Masarova L; Bose P; Pemmaraju N; Daver NG; Sasaki K; Chifotides HT; Zhou L; Kantarjian HM; Estrov Z; Verstovsek S
Cancer; 2023 Sep; 129(18):2828-2835. PubMed ID: 37243913
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
Mato A; Nabhan C; Kay NE; Lamanna N; Kipps TJ; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Kiselev P; Swern AS; Bhushan S; Sullivan K; Flick ED; Sharman JP
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):114-124.e2. PubMed ID: 29352719
[TBL] [Abstract][Full Text] [Related]
19. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
[TBL] [Abstract][Full Text] [Related]
20. Conventional cytogenetics in myelofibrosis: literature review and discussion.
Hussein K; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
